Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux
- PMID: 20658944
- DOI: 10.1089/adt.2010.0267
Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux
Abstract
In vitro screens using cellular preparations expressing human Ether-à-go-go related gene (hERG) potassium channels have become an intrinsic tool for evaluating cardiac liability of compounds during early preclinical stage development. Although hERG channel blocking effects are most reliably evaluated using the low-throughput, manual patch clamp technique, methods and technologies that yield hERG activity data in multiwell format are required to address increased throughput requirements. In most cases, multiwell approaches to measuring hERG activity involve achieving a reasonable balance between throughput and data fidelity. Here we compared two functional multiwell hERG assays: a fluorescence-based fluorometric imaging plate reader (FLIPR(®)) screen measuring thallium (Tl(+)) influx through hERG channels and an automated patch clamp assay using an IonWorks Quattro(®). Mean Z' values for FLIPR-Tl(+) and IonWorks Quattro assays were similar, 0.57 ± 0.09 (±SD; n = 10) versus 0.63 ± 0.11 (n = 12), respectively. IC₅₀ determinations for a set of 17 reference compounds were used to evaluate potency shifts relative to conventional voltage clamp data. The reference compound set included members that are known to exert severe potency shifts in multiwell assays. Mean potency shift values for FLIPR-Tl(+) and IonWorks Quattro assays were 117- and 8-fold, respectively. On the basis of reduced potency shifts and low data variability, we conclude that the IonWorks Quattro screen was a better predictor of hERG activity in conventional whole-cell patch clamp than the Tl(+) influx assay.
Similar articles
-
A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.Assay Drug Dev Technol. 2010 Dec;8(6):714-26. doi: 10.1089/adt.2010.0351. Assay Drug Dev Technol. 2010. PMID: 21158686
-
Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.Assay Drug Dev Technol. 2005 Feb;3(1):47-57. doi: 10.1089/adt.2005.3.47. Assay Drug Dev Technol. 2005. PMID: 15798395
-
Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.J Pharmacol Toxicol Methods. 2013 Jan-Feb;67(1):33-44. doi: 10.1016/j.vascn.2012.10.002. Epub 2012 Oct 26. J Pharmacol Toxicol Methods. 2013. PMID: 23103595
-
The hERG potassium channel and hERG screening for drug-induced torsades de pointes.Pharmacol Ther. 2008 Aug;119(2):118-32. doi: 10.1016/j.pharmthera.2008.05.009. Epub 2008 Jun 18. Pharmacol Ther. 2008. PMID: 18616963 Review.
-
In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.Comb Chem High Throughput Screen. 2011 Jun 1;14(5):375-87. doi: 10.2174/138620711795508322. Comb Chem High Throughput Screen. 2011. PMID: 21470179 Review.
Cited by
-
Discovery, characterization, and structure-activity relationships of an inhibitor of inward rectifier potassium (Kir) channels with preference for Kir2.3, Kir3.x, and Kir7.1.Front Pharmacol. 2011 Nov 30;2:75. doi: 10.3389/fphar.2011.00075. eCollection 2011. Front Pharmacol. 2011. PMID: 22275899 Free PMC article.
-
Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors.PLoS One. 2013 Jul 23;8(7):e69513. doi: 10.1371/journal.pone.0069513. Print 2013. PLoS One. 2013. PMID: 23936032 Free PMC article.
-
Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.J Infect Dis. 2017 Apr 15;215(8):1275-1284. doi: 10.1093/infdis/jix120. J Infect Dis. 2017. PMID: 28329187 Free PMC article.
-
High throughput screening technologies for ion channels.Acta Pharmacol Sin. 2016 Jan;37(1):34-43. doi: 10.1038/aps.2015.108. Epub 2015 Dec 14. Acta Pharmacol Sin. 2016. PMID: 26657056 Free PMC article. Review.
-
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.ACS Omega. 2021 Jan 13;6(3):2284-2311. doi: 10.1021/acsomega.0c05589. eCollection 2021 Jan 26. ACS Omega. 2021. PMID: 33521468 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources